Abstract:Background: Ventricular septal defect (VSD) is the most common congenital cardiac malformation, accounting for approximately 30% of congenital heart defects. Conventional surgical repair using cardiopulmonary bypass is invasive and associated with morbidities and prolonged hospital stay. With the advent of interventional approaches and availability of different occluding devices, the technique of perventricular device closure is evolving and being implemented successfully in larger groups of patients. We present herein, our initial experience of perventricular device closure for the ventricular septal defects in children to assess risks and benefits. Methods: From March, 2023 to February, 2024, we have performed perventricular closure of ventricular septal defects in 13 children, under guidance of transesophageal echocardiography without cardiopulmonary bypass support. The median age at operation was 2 year (range 1.3-10 years) with the median body weight 11 kg (range 8.7-16.6 kg). Sixty-nine percent were males. The ventricular septal defect sizes ranged from 2.7 to 6 mm (mean 4.7 mm). Seven defects were perimembranous, four sub-aortic and two were muscular. One patient also underwent pulmonary artery de-banding with pulmonary artery balloon angioplasty and other one patent ductus arteriosus ligation, concomitantly. For defect closure, we used ventricular septal defect occlusion device (MemoPart™, Lepu Medical Technology Company, China) through a 3-cm skin incision in the lower- third of the sternum. The device sizes ranged from 5 to 8 mm (mean 6.9+-1.8 mm) and all patients except for two required symmetrical devices. Results: All patients underwent device closure successfully. The procedural duration ranged between 32 and 52 min. None of the patients required cardiopulmonary bypass. The mean ventilation time and intensive care unit stay was 3 and 24 h, respectively. None of the patients required inotropic support or blood transfusions. Moreover, no patients developed any arrhythmias including heart block. The average length of hospital stay was 4.4 days. At the latest follow up, there were no residual shunts, conduction disturbances, device dislodgement or major aortic or tricuspid valve complications seen in any patients. There was no mortality. Conclusions: Perventricular device closure of ventricular septal defects is a less invasive, extremely safe and effective method in children. It is associated with very fast recovery, shorter hospitalization time and better cosmetic incision. Moreover, it avoids cardiopulmonary bypass. The modifications and refinements in the design, material and implantation techniques will help in expanding the indications and prevent complications in the long-term.

A Novel Inflatable Left Ventricular Partitioning Device.

Minimally Invasive Experiences on Perventricular Device Closure of Ventricular Septal Defects in Children

Minimally Invasive Perventricular Device Closure of Perimembranous Ventricular Septal Defect Without Cardiopulmonary Bypass: Multicenter Experience and Mid-Term Follow-Up

Percutaneous Ventricular Restoration Prevents Left Ventricular Remodeling Post Myocardial Infarction: One-Year Evaluation of the Heartech First-in-man Study

Percutaneous Ventricular Restoration Therapy Using the Parachute Device in Chinese Patients with Ischemic Heart Failure: Three-Month Primary End-point Results of PARACHUTE China Study.

First-in-man study of Heartech® percutaneous left ventricular partitioning device for treatment of heart failure postmyocardial infarction.

Perventricular device closure of the ventricular septal defects in children-first experience in the United Arab Emirates

Left Ventricular Hemodynamics with an Implanted Assist Device: An In Vitro Fluid Dynamics Study

Transcatheter Left Ventricular Restoration in Patients With Heart Failure

In vitro testing of an intra-ventricular assist device.

Primary experience of percutaneous ventricular restoration with Parachute system

Promotion of right ventricular outflow tract reconstruction using a novel cardiac patch incorporated with hypoxia-pretreated urine-derived stem cells

Hemodynamical Evaluation of a New Surgically Implanted Pulsatile Right Ventricular Assist Device Driven by a Conventional Intra-Aortic Balloon Pump Console

In vitro hemodynamic performance of a blood pump for self-powered venous assist in univentricular hearts

A cavalpulmonary assist device utilising impedance pumping enhanced by peristaltic effect

A Self-Expanding Percutaneous Valve for Patients with Pulmonary Regurgitation and an Enlarged Native Right Ventricular Outflow Tract: One-Year Results

Hydraulic and hemodynamic performance of a minimally invasive intra-arterial right ventricular assist device

Hybrid Transthoracic Periventricular Device Closure of Ventricular Septal Defects: Single- Center Experience

Heartech® Left Ventricular Partitioning Device Improves Left Ventricular Systolic Function of Patients with Chronic Heart Failure Post‐myocardial Infarction at 1‐year Follow‐up

Novel application of the Diabolo technique to restrict pulmonary blood flow in a single ventricle patient with a right ventricle to pulmonary artery conduit

Salutary Effects of the PULVAD, a Novel Implantable Counterpulsation Assist Device, on Cardiac Mechanoenergetics